💊Completion of Acquisition of NeuroDerm (100% Ownership)  20171018

By JPN, Pharmaceutical

💊Completion of Acquisition of NeuroDerm (100% Ownership)

With regard to the announcement “Mitsubishi Tanabe Pharma to Acquire NeuroDerm Ltd.,” which was released on July 24, 2017, Mitsubishi Tanabe Pharma Corporation (“MTPC”) hereby reports that the procedures for MTPC’s acquisition of NeuroDerm Ltd. (Nasdaq: NDRM) (“NeuroDerm”) have been completed on October 18, 2017 (IDT: Israel Daylight Time).

http://www.mt-pharma.co.jp/e/release/nr/2017/pdf/e_MTPC171018.pdf

More from tokioX :

  1. 💉To ALS patients in the world, we hope to deliver Japan-originated ALS treatment
  2. 💊Mitsubishi Tanabe Pharma and Hitachi Utilize AI Technology to Begin Collaborative Creation for Improving Efficiency of Clinical Trials for New Drug Development
  3. 💊Establish mass production technology of Toyobo and HMT, enzymes for depression related biomarkers Toyobo and Human Metabolome Technologies have established mass-production technologies for enzymes used for measuring depression-related biomarkers through collaborative research.
  4. 💊Takeda and HemoShear Therapeutics Enter into Exclusive Drug Discovery Partnership in Liver Diseases
  5. 💊Kyowa Hakko Kirin Announces the Intent to File Istradefylline (KW-6002) for Parkinson’s Disease with the US FDA
  6. 💊Mitsubishi Tanabe Pharma Corporation] Notice regarding acquisition of manufacturing and sales approval for Rupafin tablets Allergy treatment agent with new mechanism of action shows strong effectiveness with dual action (anti-PAF and antihistamine action)  20170927
  7. Takeda and Noile-Immune Biotech Collaborate to Advance Next Generation CAR-T Cell Therapy Effective for Solid Tumors